Traveka Wealth LLC Has $412,000 Position in Abbott Laboratories (NYSE:ABT)

Traveka Wealth LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 77.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,643 shares of the healthcare product maker’s stock after acquiring an additional 1,592 shares during the period. Traveka Wealth LLC’s holdings in Abbott Laboratories were worth $412,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. First Financial Corp IN grew its holdings in shares of Abbott Laboratories by 1.2% during the 4th quarter. First Financial Corp IN now owns 16,634 shares of the healthcare product maker’s stock valued at $1,881,000 after purchasing an additional 195 shares during the last quarter. Tsfg LLC boosted its holdings in shares of Abbott Laboratories by 12.6% during the 4th quarter. Tsfg LLC now owns 106,061 shares of the healthcare product maker’s stock valued at $11,997,000 after acquiring an additional 11,836 shares in the last quarter. PFW Advisors LLC bought a new stake in Abbott Laboratories during the 4th quarter worth $2,335,000. Miracle Mile Advisors LLC increased its holdings in Abbott Laboratories by 228.6% in the 4th quarter. Miracle Mile Advisors LLC now owns 35,829 shares of the healthcare product maker’s stock worth $4,053,000 after purchasing an additional 24,925 shares in the last quarter. Finally, Horizon Wealth Management LLC raised its position in Abbott Laboratories by 35.9% in the fourth quarter. Horizon Wealth Management LLC now owns 3,180 shares of the healthcare product maker’s stock valued at $360,000 after purchasing an additional 840 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Morgan Stanley upped their price objective on Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 17th. Sanford C. Bernstein upped their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Royal Bank of Canada boosted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Jefferies Financial Group increased their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research note on Thursday, October 17th. Finally, Raymond James reissued a “buy” rating and set a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.57.

Abbott Laboratories Stock Performance

ABT opened at $113.12 on Tuesday. The company has a market cap of $196.20 billion, a price-to-earnings ratio of 34.38, a PEG ratio of 2.69 and a beta of 0.73. The company’s fifty day moving average price is $115.23 and its two-hundred day moving average price is $112.60. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $121.64. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. Abbott Laboratories’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 earnings per share. On average, analysts expect that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 71.73%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.